A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects

Tan Zhang,Guihong Chen,Chang Liu,Li’an Zu,Qi Wang,Yitong Wang,Jie Lv,Youzhong An,Lihou Dong,Huiyang Cheng,Shengbin Ren,Qian Wang,Qingshan Zheng,Haifeng Song,Yi Fang

A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects

2019

Tan Zhang
Guihong Chen
Chang Liu
Li’an Zu
Qi Wang
Yitong Wang
Jie Lv
Youzhong An
Lihou Dong
Huiyang Cheng
Shengbin Ren
Qian Wang
Qingshan Zheng
Haifeng Song
Yi Fang

Objective The objective of this study was to compare the pharmacokinetics (PKs), safety, and immunogenicity of GB242 as a potential biosimilar infliximab with those of reference infliximab in healthy Chinese subjects.

Keywords:

Biosimilar
Immunology
Pharmacology
Immunogenicity
Infliximab
Pharmacokinetics
Medicine
chinese subjects
phase i study
Pharmacotherapy
healthy subjects

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations